Fat-Blocking Pill From GlaxoSmithKline May Be Sold Without Prescription
Filed in archive Drugs, Vaccines and Therapeutics on January 25, 2006
Following an 11-3 result of a votation among the FDA Advisory panel, GlaxoSmithKline's weight-loss pill, Alli (60 mg orlistat, half the Dosage of Roche's Xenical), might be the first fat-blocking pill available in the market without prescription.
When taken with meals, orlistat blocks the absorption of about one-quarter of any fat consumed. That fat _ about 150 to 200 calories' worth _ is passed out of the body in stools, which can be loose as a result. About half of patients in trials experienced gastrointestinal side effects, the company said.
Of course, orlistat is no magic pill. There are side effects and is effective only for the duration of pill intake. However, it can be a tool that will help people control their calorie intake and modify their diet. The advisory panel requested Glaxo to continue follow-up studies should the product make it to the over-the-counter market, and to rework its label to ensure its proper use and avoid its abuse.
Read more from the Washington Posthere and here..
Tags: xenical weightloss biotech pill without blocking+pill without+prescription sold+without
Vote for Fat-Blocking Pill From GlaxoSmithKline May Be Sold Without Prescription:
|
Rating: 8.00 out of 1 vote(s) cast.
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells
